InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the detailed record of transactions filed by Nova Tina Susan, Présidente. Officer active across 3 companies, notably Arena Pharmaceuticals INC. Cumulatively, 8 filings have been published. History available since 11 June 2021. The latest transaction was filed on 6 February 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Nova Tina Susan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报8 总计
5,663 股@ US$27.8527.4% 占其流量CommonSEC:0001193125-26-041527:0
4,040 股@ US$52.3257.5% 占其流量CommonSEC:0000950170-25-017893:0
2,465 股@ US$65.9342.5% 占其流量CommonSEC:0000950170-24-014558:0
3,604 股0Common StockSEC:0001209191-23-009725:0
17,776 股Common StockSEC:0001628280-22-005918:0
56,546 股0Common StockSEC:0001384101-22-000052:0
10,695 股@ US$27.84100.0% 占其流量Common StockSEC:0001384101-22-000038:0
3,067 股0Common StockSEC:0001628280-21-012279:0
8 条申报中的 8 条
About Nova Tina Susan
Tina Susan Nova is the President and CLIA U.S. Operations Director at ARENA PHARMACEUTICALS INC and VERACYTE, INC. She oversees the operational and strategic activities of both companies, bringing her expertise in the life sciences field. Her role is essential in ensuring regulatory compliance and innovation in product development. Through her leadership, she contributes to the growth and success of the organizations.
